Abu Dhabi-based femtech startup Ovasave has secured $1.2 million in pre-seed funding to scale its digital health platform across the GCC region. The round was led by PlusVC, Annex Investments, and New York-based 25 Madison, with additional support from strategic angel investors and family offices in the UAE and Saudi Arabia.
Founded in 2023, Ovasave focuses on fertility and hormonal health through a digital-first service offering hormone testing, egg freezing, virtual consultations, and menopause care. The platform combines at-home diagnostic tools with personalized care protocols and provides access to fertility clinics.
“There is a critical need for timely intervention in women’s health, particularly around fertility and hormonal health,” said Torkia Mahloul, Co-founder and CEO of Ovasave. “This funding marks a crucial step in our mission to disrupt women’s health and expand access to fertility and hormonal care across the region.”
The company operates a corporate benefits program designed to help organizations offer reproductive health services as part of employee wellbeing strategies. This B2B approach targets the growing demand for comprehensive workplace health benefits in the region.
According to FemTech Analytics, the femtech market in the region is projected to reach $3.8 billion by 2031, growing at a 15% CAGR from 2021 to 2031. The funding will support Ovasave’s regional expansion, scaling of employer partnerships, and development of enhanced mobile app features.
Planned app updates include menstrual cycle tracking, symptom monitoring, AI-supported treatment recommendations, and expanded menopause support. These features aim to provide comprehensive hormonal health management throughout women’s reproductive lifecycles.
